|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US8470359||TOLMAR||Sustained release polymer|| |
(16 days from now)
Fensolvi Kit is owned by Tolmar.
Fensolvi Kit contains Leuprolide Acetate.
Fensolvi Kit has a total of 1 drug patent out of which 0 drug patents have expired.
Fensolvi Kit was authorised for market use on 01 May, 2020.
Fensolvi Kit is available in powder;subcutaneous dosage forms.
Fensolvi Kit can be used as method of treating pediatric patients 2 years of age and older with central precocious puberty.
The generics of Fensolvi Kit are possible to be released after 15 October, 2023.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Indication (I)||May 1, 2023|
Market Authorisation Date: 01 May, 2020
Treatment: Method of treating pediatric patients 2 years of age and older with central precocious puberty
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic